CNS Pharma rises on dosing first patient in a global brain cancer trial

CNS Pharmaceuticals

02/11/2022 17:37

** Shares of drug developer CNS Pharmaceuticals Inc  CNSP.O 
rise 21.71% to $0.21
    ** Co enrolls and doses first patient in France in an
ongoing potentially pivotal global trial evaluating its drug in
treating recurrent glioblastoma multiforme (GBM)  urn:newsml:reuters.com:*:nPn9fyFWra
    ** GBM is one of the most aggressive types of brain cancer 
    ** CNSP says the drug, berubicin, has received "fast track"
designation from the U.S. FDA, enabling more frequent
interactions with the agency
    ** Also says the drug has received "orphan drug" designation
from U.S. FDA 
    ** Co testing the efficacy and safety of the drug in adult
patients with GBM, has opened 29 clinical trial sites of the 68
sites selected across the U.S., Italy, France, Spain, and
Switzerland
    ** U.S. health regulator's orphan drug status is given to
drugs that treat rare conditions and are protected through a
series of government incentives after launch
    ** Including session gains, stock down 70.5% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))